Novo Nordisk reports results of faster-acting insulin aspart and NovoRapid diabetes comparison

26 March 2015

Danish insulin giant Novo Nordisk (NOV: N) has completed Phase IIIa trials comparing faster-acting insulin aspart with NovoRapid in type 1 and type 2 diabetes.

The trials investigated the efficacy and safety of faster-acting insulin aspart compared with NovoRapid (insulin aspart) in a basal-bolus regimen in patients with type 1 and type 2 diabetes, respectively.

Both trials met their primary endpoints in demonstrating that treatment with faster-acting insulin aspart is non-inferior to NovoRapid in lowering HbA1c. In type 1 diabetes, HbA1c lowering achieved with faster-acting insulin aspart was statistically significantly larger than that achieved with NovoRapid when the insulins were administered at mealtime. Treatment with faster-acting insulin aspart was associated with less increase of postprandial glucose than NovoRapid during meal tests in both trials.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK